People News: Affymax, Neogenix Oncology and ProBioGen AG

Affymax promoted Sylvia Wheeler to VP, corporate communications. Wheeler has more than 20 years of corporate communications and investor relations experience in the bioscience industry and is a member of the board of directors for the National Kidney Foundation Northwestern US Division.

Neogenix Oncology, Inc. has named Philip M. Arlen, MD its CEO. Arlen joined Neogenix as president and chief medical officer of the company in July 2008. Prior to 2008, he spent 11 years at the National Cancer Institute, USA, most recently as the director of the clinical research group for the Laboratory of Tumor Immunology and Oncology.

ProBioGen AG announced that Dr. Volker Sandig has been appointed to chief scientific officer (CSO) of the company. He will take over the duties of Dr. Uwe Marx, who will take an opportunity to lead an entrepreneurial innovation team at the Technical University Berlin.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.